Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 23

Sort by

Sort Order Select

Journal Articles

Novel MAGIC composite scores using both clinical symptoms and biomarkers best predict treatment outcomes of acute GVHD

Blood (2024) 144 (9): 1010–1021.

https://doi.org/10.1182/blood.2024025106

Published: 2024

Includes: Supplemental data

Journal Articles

Platelet Subpopulations and Distinct Platelet Function Defects after Hematopoietic Stem Cell Transplantation in Mice and Humans

Kristina Mott, Lukas Johannes Weiss, Margret Droste, Maria Drayss, Sabrina Kraus, Torsten Steinbrunn, Harald Schulze

Blood (2023) 142 (Supplement 1): 348.

https://doi.org/10.1182/blood-2023-180641

Published: 2023

Journal Articles

A Day 14 Endpoint for Acute Gvhd Clinical Trials

Blood (2023) 142 (Supplement 1): 779.

https://doi.org/10.1182/blood-2023-172955

Published: 2023

Journal Articles

Updated Results from a Phase I Dose Escalation Study of the Rapidly-Switchable Universal CAR-T Therapy UniCAR-T-CD123 in Relapsed/Refractory AML

Martin Wermke, Stephan Metzelder, Sabrina Kraus, Elisa Sala, Vladan Vucinic, Walter Fiedler, Katrin Wetzko, Jonas Schäfer, Maria-Elisabeth Goebeler, Jan Koedam, Kristin Franke, Matti Vänskä, Armin Ehninger, Marc Cartellieri, Gerhard Ehninger, Tapan Maniar

Blood (2023) 142 (Supplement 1): 3465.

https://doi.org/10.1182/blood-2023-177867

Published: 2023

Journal Articles

Flares of Acute Graft-Versus-Host Disease: Mount Sinai Acute Gvhd International Consortium (MAGIC) Study

Blood (2023) 142 (Supplement 1): 776.

https://doi.org/10.1182/blood-2023-181900

Published: 2023

Journal Articles

Venetoclax Plus High-Dose Cytarabine and Mitoxantrone (HAM-Ven) As Salvage Treatment for Relapsed/Refractory AML: Updated Results of the Phase-I/II SAL Relax Trial

Blood (2023) 142 (Supplement 1): 160.

https://doi.org/10.1182/blood-2023-184445

Published: 2023

Journal Articles

Venetoclax-Based Salvage Therapy Improves Outcome in Relapsed/Refractory AML Patients Eligible for Intensive Treatment: A Propensity Score Matching Analysis

Blood (2022) 140 (Supplement 1): 3317–3319.

https://doi.org/10.1182/blood-2022-167677

Published: 2022

Journal Articles

Immune Checkpoint CD200/CD200R Decreases T Cell-Mediated Cytotoxicity Via Dok2 and Is Regulated By P53 in Multiple Myeloma

Pooja Shah, Thorsten Stuehmer, Larissa Haertle, Daniela Bruennert, Umair Munawar, Ellen Leich, Sabrina Kraus, Michael Hudecek, Manik Chatterjee, Andreas Schlosser, Martin Kortuem, Ralf C Bargou, Hermann Einsele, Friederike Berberich-Siebelt, Torsten Steinbrunn

Blood (2022) 140 (Supplement 1): 7076–7077.

https://doi.org/10.1182/blood-2022-166283

Published: 2022

Journal Articles

Phase 1 Dose Escalation Study of the Rapidly Switchable Universal CAR-T Therapy Unicar-T-CD123 in Relapsed/Refractory AML

Gerhard Ehninger, Sabrina Kraus, Elisa Sala, Stephan K Metzelder, Vladan Vucinic, Walter Fiedler, Maria-Elisabeth Goebeler, Jan Moritz Middeke, Malte von Bonin, Carla Kreissig, Jan Koedam, Marc Cartellieri, Armin Ehninger, Martin Wermke, Jonas A. Schäfer

Blood (2022) 140 (Supplement 1): 2367–2368.

https://doi.org/10.1182/blood-2022-168877

Published: 2022

Journal Articles

Venetoclax Plus High-Dose Cytarabine and Mitoxantrone As Feasible and Effective Novel Treatment for Relapsed AML: Results of the Phase-I SAL Relax Trial

Blood (2022) 140 (Supplement 1): 3327–3328.

https://doi.org/10.1182/blood-2022-159897

Published: 2022

Journal Articles

Siglec-6 is a novel target for CAR T-cell therapy in acute myeloid leukemia

Hardikkumar Jetani, Almudena Navarro-Bailón, Marius Maucher, Silke Frenz, Christina Verbruggen, Ana Yeguas, María Belén Vidriales, Marcos González, Judit Rial Saborido, Sabrina Kraus, Katrin Mestermann, Simone Thomas, Halvard Bonig, Maik Luu, Razieh Monjezi, Dimitrios Mougiakakos, Markus Sauer, Hermann Einsele, Michael Hudecek

Blood (2021) 138 (19): 1830–1842.

https://doi.org/10.1182/blood.2020009192

Published: 2021

Includes: Supplemental data

Journal Articles

Real-World Experience of CPX-351 As First-Line Treatment in 188 Patients with Acute Myeloid Leukemia

Christina Rautenberg, Friedrich Stölzel, Christoph Röllig, Matthias Stelljes, Verena I Gaidzik, Michael Lauseker, Oliver Kriege, Mareike Verbeek, Julia M. Unglaub, Felicitas Thol, Stefan W. Krause, Mathias Haenel, Charlotte Neuerburg, Vladan Vucinic, Christian Jehn, Julia Severmann, Maxi Wass, Lars Fransecky, Jens Chemnitz, Udo Holtick, Kerstin Schäfer-Eckart, Josephine Schröder, Sabrina Kraus, William Hermann Krüger, Ulrich Kaiser, Sebastian Scholl, Lea Henning, Guido Kobbe, Rainer Haas, Nael Alakel, Maximilian Alexander Röhnert, Katja Sockel, Maher Hanoun, Uwe Platzbecker, Tobias A. W. Holderried, Anke Morgner, Michael Heuser, Tim Sauer, Katharina S. Goetze, Eva Maria Wagner, Konstanze Döhner, Hartmut Döhner, Christoph Schliemann, Johannes Schetelig, Martin Bornhäuser, Ulrich Germing, Thomas Schroeder, Moritz Moritz Middeke

Blood (2021) 138 (Supplement 1): 33.

https://doi.org/10.1182/blood-2021-153440

Published: 2021

Journal Articles

Intensified Cytarabine Dose during Consolidation Therapy in AML Patients Under 65 Years Is Not Associated with Survival Benefit

Blood (2021) 138 (Supplement 1): 1242.

https://doi.org/10.1182/blood-2021-146606

Published: 2021

Journal Articles

Characteristics and Outcome of Patients with Acute Myeloid Leukemia and Trisomy 4

Blood (2021) 138 (Supplement 1): 1307.

https://doi.org/10.1182/blood-2021-150281

Published: 2021

Journal Articles

Impact of Body Mass Index on Patient Outcome in Acute Myeloid Leukemia Patients Receiving Intensive Induction Therapy: A Real-World Registry Experience

Blood (2021) 138 (Supplement 1): 3370.

https://doi.org/10.1182/blood-2021-145917

Published: 2021

Journal Articles

Venetoclax-Azacitidine As Salvage Therapy and Bridge to Allogeneic Cell Transplantation in Relapsed/Refractory AML Compared to Historical Data of the SAL Registry Study

Blood (2021) 138 (Supplement 1): 4418.

https://doi.org/10.1182/blood-2021-151287

Published: 2021

Journal Articles

CD200 Expression on Multiple Myeloma Cells Induces Attenuation of T Cell-Mediated Cytotoxicity Via DOK2

Pooja Shah, Thorsten Stuehmer, Daniela Bruennert, Umair Munawar, Ellen Leich, Sabrina Kraus, Michael Hudecek, Manik Chatterjee, Andreas Schlosser, Ralf C Bargou, Hermann Einsele, Friederike Berberich-Siebelt, Torsten Steinbrunn

Blood (2021) 138 (Supplement 1): 1587.

https://doi.org/10.1182/blood-2021-153741

Published: 2021

Journal Articles

Genetic risk of CMV reactivation?

Hermann Einsele, Sabrina Kraus

Blood (2021) 138 (17): 1516–1517.

https://doi.org/10.1182/blood.2021013242

Published: 2021

Journal Articles

Proof of concept for a rapidly switchable universal CAR-T platform with UniCAR-T-CD123 in relapsed/refractory AML

Martin Wermke, Sabrina Kraus, Armin Ehninger, Ralf C. Bargou, Maria-Elisabeth Goebeler, Jan Moritz Middeke, Carla Kreissig, Malte von Bonin, Jan Koedam, Michael Pehl, Martin Bornhäuser, Hermann Einsele, Gerhard Ehninger, Marc Cartellieri

Blood (2021) 137 (22): 3145–3148.

https://doi.org/10.1182/blood.2020009759

Published: 2021

Journal Articles

RAC1 Inhibitor EHT1864 and Venetoclax Overcome Midostaurin Resistance in Acute Myeloid Leukemia

Blood (2019) 134 (Supplement_1): 1277.

https://doi.org/10.1182/blood-2019-129762

Published: 2019

NARROW

Novel MAGIC composite scores using both clinical symptoms and biomarkers best predict treatment outcomes of acute GVHD

Platelet Subpopulations and Distinct Platelet Function Defects after Hematopoietic Stem Cell Transplantation in Mice and Humans

A Day 14 Endpoint for Acute Gvhd Clinical Trials

Updated Results from a Phase I Dose Escalation Study of the Rapidly-Switchable Universal CAR-T Therapy UniCAR-T-CD123 in Relapsed/Refractory AML

Flares of Acute Graft-Versus-Host Disease: Mount Sinai Acute Gvhd International Consortium (MAGIC) Study

Venetoclax Plus High-Dose Cytarabine and Mitoxantrone (HAM-Ven) As Salvage Treatment for Relapsed/Refractory AML: Updated Results of the Phase-I/II SAL Relax Trial

Venetoclax-Based Salvage Therapy Improves Outcome in Relapsed/Refractory AML Patients Eligible for Intensive Treatment: A Propensity Score Matching Analysis

Immune Checkpoint CD200/CD200R Decreases T Cell-Mediated Cytotoxicity Via Dok2 and Is Regulated By P53 in Multiple Myeloma

Phase 1 Dose Escalation Study of the Rapidly Switchable Universal CAR-T Therapy Unicar-T-CD123 in Relapsed/Refractory AML

Venetoclax Plus High-Dose Cytarabine and Mitoxantrone As Feasible and Effective Novel Treatment for Relapsed AML: Results of the Phase-I SAL Relax Trial

Siglec-6 is a novel target for CAR T-cell therapy in acute myeloid leukemia

Real-World Experience of CPX-351 As First-Line Treatment in 188 Patients with Acute Myeloid Leukemia

Intensified Cytarabine Dose during Consolidation Therapy in AML Patients Under 65 Years Is Not Associated with Survival Benefit

Characteristics and Outcome of Patients with Acute Myeloid Leukemia and Trisomy 4

Impact of Body Mass Index on Patient Outcome in Acute Myeloid Leukemia Patients Receiving Intensive Induction Therapy: A Real-World Registry Experience

Venetoclax-Azacitidine As Salvage Therapy and Bridge to Allogeneic Cell Transplantation in Relapsed/Refractory AML Compared to Historical Data of the SAL Registry Study

CD200 Expression on Multiple Myeloma Cells Induces Attenuation of T Cell-Mediated Cytotoxicity Via DOK2

Genetic risk of CMV reactivation?

Proof of concept for a rapidly switchable universal CAR-T platform with UniCAR-T-CD123 in relapsed/refractory AML

RAC1 Inhibitor EHT1864 and Venetoclax Overcome Midostaurin Resistance in Acute Myeloid Leukemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only